- **6**. The method of claim **5**, wherein the at least one antigen's antibody/antigen attachment site is used as a vaccine administered to an animal for creation of antibodies specific to the antigen's antibody/antigen attachment site.
- 7. A method of treating a subject who has cancer of claim 6 comprising administering to said subject a therapeutically effective amount of the antibodies specific to the antigen's antibody/antigen attachment site, wherein the antibodies are either unmodified or modified.
- **8**. A method of detecting B cells which generate antibodies against the cancer cells in the subject who has cancer, comprising the steps of:
  - a. determining the amino acid sequence of the at least one
    of the antigen's antibody/antigen attachment sites of
    claim 5 and synthesizing and labeling a peptide comprising at least part of the said amino acids sequence,
    or labeling the at least one of the antigen's antibody/
    antigen attachment sites of claim 5; and,

- b. incubating the labeled peptide or labeled at least one of the labeled antigen's antibody/antigen attachment sites of step b with the serum obtained from the subject who has cancer, and allowing time for specific binding between the labeled peptides and B cells.
- 9. The method of claim 8, wherein the type of label of the peptide of step a is selected from a group comprising radioactive isotopes, radiolabeled amino acid, and/or fluorescent amino acids.
- 10. The method of claim 9, wherein the labeled B cells are isolated, cell cultured, and induced to produce the cancerspecific antibodies.
- 11. A method of treating a subject who has cancer, comprising administering to said subject a therapeutically effective amount of the B cells of claim 10.
- 12. A method of treating a subject who has cancer, comprising administering to said subject a therapeutically effective amount of the antibodies, and/or their derivatives, produced by the B cells of claim 10.

\* \* \* \* \*